E. Van-cutsem, A. Cervantes, and R. Adam, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, vol.27, issue.8, pp.1386-1422, 2016.

A. Lièvre, J. L. Merlin, and P. Laurent-puig, Flash RAS study: RAS testing assessment in patients with metastatic colorectal cancer in 2014, Eur J Cancer, vol.51, p.85, 2015.

C. Barone, C. Pinto, and N. Normanno, KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting, PLoS One, vol.9, issue.1, p.85897, 2014.

V. Heinemann, L. F. Von-weikersthal, and T. Decker, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, vol.15, issue.10, pp.1065-1075, 2014.

V. Taly, D. Pekin, and L. Benhaim, Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1731, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

C. Bettegowda, M. Sausen, and R. J. Leary, Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014.

A. R. Thierry, F. Mouliere, E. Messaoudi, and S. , Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, issue.4, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

J. Wan, C. Massie, and J. Garcia-corbacho, Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat Rev Cancer, vol.17, issue.4, pp.223-238, 2017.

J. Y. Douillard, G. Ostoros, and M. Cobo, Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, issue.9, pp.1345-1353, 2014.

N. Pécuchet, Y. Rozenholc, and E. Zonta, Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA, Clin Chem, vol.62, issue.11, pp.1492-1503, 2016.

S. Garrigou, G. Perkins, and F. Garlan, A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin Chem, vol.62, issue.8, pp.1129-1139, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02295782

F. Garlan, P. Laurent-puig, and D. Sefrioui, Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study), Clin Cancer Res, vol.23, issue.18, pp.5416-5425, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02299521

J. Vidal, L. Muinelo, and A. Dalmases, Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients, Ann Oncol, vol.28, issue.6, pp.1325-1332, 2017.

A. R. Thierry, S. El-messaoudi, and C. Mollevi, Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment, Ann Oncol, vol.28, issue.9, pp.2149-2159, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01682168

A. M. Baker, W. Huang, and X. M. Wang, Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution, Nat Commun, vol.8, issue.1, 1998.

H. Blons, E. Rouleau, and N. Charrier, Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience, PLoS One, vol.8, p.68945, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00974911

J. Grasselli, E. Elez, and G. Caratu, Concordance of blood-and tumorbased detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer, Ann Oncol, vol.28, issue.6, pp.1294-1301, 2017.

D. Pietrasz, N. Pécuchet, and F. Garlan, Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker, Clin Cancer Res, vol.23, issue.1, pp.116-123, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01458933